Agios pharmaceuticals, inc. (AGIO)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Operating activities
Net loss

-411,472

-346,028

-314,670

-198,471

-117,732

-53,504

-39,407

-20,102

-23,706

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

8,087

7,172

6,432

5,700

3,342

1,367

1,440

1,179

801

Stock-based compensation expense

72,373

73,357

47,809

42,086

31,963

11,506

3,030

742

371

Deferred taxes

-

-

-

-

-

-

3,842

6,707

-10,660

Net accretion of premium and discounts on investments

3,195

3,837

11

-773

-539

-538

-284

-287

-391

Loss on disposal of property and equipment

-1,052

-20

-40

0

-33

-

-

-10

-

Non-cash operating lease expense

8,532

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, net

3,876

5,076

0

0

-

-

-

-

-

Collaboration receivable – related party

-923

14

-2,438

-3,339

1,733

6,016

476

-

-

Collaboration receivable – other

1,258

670

0

0

-

-

-

-

-

Royalty receivable – related party

666

1,012

1,222

0

0

-

-

-

-

Inventory

6,462

869

0

0

-

-

-

-

-

Tenant improvement and other receivables

-

-

-

-

1,040

2,334

-

-

-

Prepaid expenses and other current and non-current assets

7,742

-1,148

3,600

2,420

3,768

2,878

1,562

94

63

Accounts payable

3,716

-5,488

5,329

3,501

4,215

7,577

30

-322

809

Accrued expenses

7,233

8,623

1,522

16,854

1,633

5,231

4,878

156

525

Deferred revenue – related party

-31,006

-31,665

-26,570

165,846

-14,047

-19,228

-25,072

-25,072

-1,797

Operating lease liabilities

-6,861

-

-

-

-

-

-

-

-

Deferred rent

0

82

2,729

-1,346

-15,805

-3,691

85

46

-243

Refundable income taxes and income taxes payable

-

-

-

-

3,841

-5,303

-3,302

-12,993

17,867

Net cash used in operating activities

-370,622

-304,421

-285,232

38,562

-76,949

-59,353

-56,400

-49,548

-15,219

Investing activities
Proceeds from maturities and sales of marketable securities

592,177

666,481

635,421

396,632

501,650

505,528

60,126

113,041

85,482

Investing activities
Purchases of marketable securities

488,566

933,320

688,702

506,067

353,177

837,219

146,049

88,524

105,936

Purchases of property and equipment

12,171

6,986

4,627

9,915

20,164

2,216

1,294

1,475

1,906

Net cash provided by investing activities

91,440

-273,825

-57,908

-119,350

128,309

-333,336

-87,217

23,042

-22,360

Financing activities
Proceeds from public offering of common stock, net of reimbursements

277,201

516,206

270,250

162,150

0

333,577

113,367

-

-

Release of restricted cash

-

-

-

-

-

571

-

-

-

Payments on financing lease obligations

113

-

-

-

-

-

-

-

-

Proceeds from private placement

-

-

-

-

-

-

12,750

-

-

Reimbursement (payment) of public offering costs

0

391

638

230

207

720

2,387

-

-

Net proceeds from stock option exercises and employee stock purchase plan

12,523

30,209

14,222

7,858

6,580

2,303

150

142

57

Net proceeds from issuance of Series C convertible preferred stock

-

-

-

-

-

-

-

-

77,301

Net cash provided by financing activities

289,611

546,024

285,110

169,778

6,373

335,160

123,880

142

77,358

Net change in cash and cash equivalents

10,429

-32,222

-58,030

88,990

57,733

-57,529

-19,737

-26,364

39,779

Supplemental cash flow information
Cash paid for income taxes

-

-

-

-

-

5,980

-

3,549

-

Supplemental disclosure of non-cash investing and financing transactions
Conversion of convertible preferred stock upon initial public offering

-

-

-

-

-

-

115,923

-

-

Vesting of restricted stock

-

-

-

-

6

9

64

-

-

Additions to property and equipment in accounts payable and accrued expenses

5,168

1,106

1,011

73

2,163

2,118

339

57

275

Proceeds from stock option exercises in other current assets

0

7

0

32

186

20

-

-

-

Operating lease liabilities arising from obtaining operating lease assets

42,322

-

-

-

-

-

-

-

-

Financing lease liabilities arising from obtaining financing lease assets

1,052

-

-

-

-

-

-

-

-

Public offering costs in other current assets, net of amounts in accounts payable and accrued expenses

-

-

-

230

0

236

-

-

-